Publication Name	World Journal of Hepatology
Manuscript ID	56722
Country	Brazil

Received	2020-06-04 20:48
Peer-Review Started	2020-06-04 20:48
To Make the First Decision
Return for Revision	2020-06-20 21:39
Revised	2020-06-29 17:57
Second Decision	2020-08-05 07:56
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2020-08-16 15:28
Articles in Press	2020-08-16 15:28
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2020-08-27 07:31
Publish the Manuscript Online	2020-09-21 16:02

ISSN	1948-5182 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Prospective Study
Article Title	Can gadoxetic acid–enhanced magnetic resonance imaging be used to avoid liver biopsy in patients with nonalcoholic fatty liver disease?
Manuscript Source	Unsolicited Manuscript
All Author List	Viviane Brandão Amorim, Daniella Braz Parente, Fernando Fernandes Paiva, Jaime Araújo Oliveira Neto, Amanda Almeida Miranda, Cláudia Cravo Moreira, Flávia Ferreira Fernandes, Carlos Frederico Ferreira Campos, Nathalie Carvalho Leite, Renata de Mello Perez and Rosana Souza Rodrigues
ORCID	Author(s) ORCID Number Viviane Brandão Amorim http://orcid.org/0000-0001-9339-1474 Daniella Braz Parente http://orcid.org/0000-0003-0031-5785 Fernando Fernandes Paiva http://orcid.org/0000-0002-8989-9707 Jaime Araújo Oliveira Neto http://orcid.org/0000-0003-0044-7622 Amanda Almeida Miranda http://orcid.org/0000-0002-9209-2314 Cláudia Cravo Moreira http://orcid.org/0000-0002-0222-4353 Flávia Ferreira Fernandes http://orcid.org/0000-0002-3149-3667 Carlos Frederico Ferreira Campos http://orcid.org/0000-0002-2623-1160 Nathalie Carvalho Leite http://orcid.org/0000-0001-9066-0405 Renata de Mello Perez http://orcid.org/0000-0002-3367-9991 Rosana Souza Rodrigues http://orcid.org/0000-0002-9952-3834
Funding Agency and Grant Number	Funding Agency Grant Number D’Or Institute for Research and Education CAAE-50521015.2.0000.5249
Corresponding Author	Viviane Brandão Amorim, MD, PhD, Research Scientist, Staff Physician, Research Department, D’Or Institute for Research and Education, No. 30 Rua Diniz Cordeiro, Botafogo, Rio de Janeiro 22281-100, Brazil. viviane1brandao@gmail.com
Key Words	Fatty liver; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis; Gadoxetic acid; ;
Core Tip	Nonalcoholic fatty liver disease (NAFLD) is a major cause of liver disease worldwide. The diagnosis of nonalcoholic steatohepatitis, the most severe form of NAFLD, is crucial and has prognostic and therapeutic implications. However, currently this diagnosis is based on liver biopsy. In this study, we demonstrated that gadoxetic acid–enhanced magnetic resonance imaging could be useful for the evaluation of patients with NAFLD, as it allows stratification according to the probabilities of nonalcoholic steatohepatitis and isolated steatosis, thereby avoiding liver biopsy in many patients.
Publish Date	2020-09-21 16:02
Citation	Amorim VB, Parente DB, Paiva FF, Oliveira Neto JA, Miranda AA, Moreira CC, Fernandes FF, Campos CFF, Leite NC, Perez RM, Rodrigues RS. Can gadoxetic acid–enhanced magnetic resonance imaging be used to avoid liver biopsy in patients with nonalcoholic fatty liver disease? World J Hepatol 2020; 12(9): 661-671
URL	https://www.wjgnet.com/1948-5182/full/v12/i9/661.htm
DOI	https://dx.doi.org/ 10.4254/wjh.v12.i9.661

Full Article (PDF)	WJH-12-661.pdf
Full Article (Word)	WJH-12-661.docx
Manuscript File	56722-Review.docx
Answering Reviewers	56722-Answering reviewers.pdf
Audio Core Tip	56722-Audio core tip.m4a
Biostatistics Review Certificate	56722-Biostatistics statement.pdf
Clinical Trial Registration Statement	56722-Clinical trial registration statement.pdf
Conflict-of-Interest Disclosure Form	56722-Conflict-of-interest statement.pdf
Copyright License Agreement	56722-Copyright license agreement.pdf
Approved Grant Application Form(s) or Funding Agency Copy of any Approval Document(s)	56722-Grant application form(s).pdf
Signed Informed Consent Form(s) or Document(s)	56722-Informed consent statement.pdf
Institutional Review Board Approval Form or Document	56722-Institutional review board statement.pdf
Non-Native Speakers of English Editing Certificate	56722-Language certificate.pdf
Peer-review Report	56722-Peer-review(s).pdf
Scientific Misconduct Check	56722-Scientific misconduct check.pdf
Scientific Editor Work List	56722-Scientific editor work list.pdf
CrossCheck Report	56722-CrossCheck report.pdf